Wang Z, et al. - In this study of two independent cohorts of patients (48 in cohort 1 and 50 in cohort 2), researchers assessed the optimal gene panel size and algorithm to design a cancer gene panel for estimating tumor mutational burden (TMB), assessed the panel reliability and further validated the feasibility of blood TMB (bTMB) as a clinical actionable biomarker for immunotherapy. According to findings, the established NCC-GP150 with an optimized gene panel size and algorithm is feasible for estimating bTMB, which can serve as a possible clinical benefit biomarker in anti-programmed cell death 1 and anti-programmed cell death ligand 1-treated patients with non-small cell lung cancer.